Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.

Leave A Comment

Your email address will not be published. Required fields are marked *